DEM BioPharma lures Takeda exec to head leadership team

Cambridge, USA-base immuno-oncology company DEM BioPharma has appointment of Nenad Grmusa as chief executive and Christophe Quéva, as chief scientific officer.

After two decades with Japanese pharma giant Takeda (TYO: 4502) and prior to its acquisition by Takeda, he was an executive at Millennium Pharmaceutical, Mr Grmusa is leaving his role as the head of the R&D Strategy and External Innovation (RESI) group to take on his first CEO role.

Previously, Mr Grmusa supported Millennium Pharmaceuticals in various financial planning and analytical roles with increasing responsibilities, and three years with Boston Biomedical Consultants. Mr Grmusa holds an M.A. in International Economics and Finance from Brandeis University and a BS in Finance from West Virginia University.